Lung cancer is one of the most common malignancies in the world. The annual incidence and mortality in eastern Asia (Japan, China, Korea and Mongolia) are estimated to be 650 000 and 550 000, respectively ([@bib4]). About 85% of lung cancer cases are histologically diagnosed as non-small cell lung cancer (NSCLC). A platinum-based chemotherapy is currently the first-line treatment for advanced or recurrent NSCLC without mutated epidermal growth factor receptor (EGFR). Many options are available for second- and third-line treatment of NSCLCs, however, the effects of these therapies are modest with a 5-year survival rate of 15% ([@bib6]).

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been recently developed for the treatment of advanced or recurrent NSCLC and proven to be particularly effective in the NSCLC harbouring driver mutations in EGFRs, such as exon 19-deletion or L858R mutation ([@bib18]). The incidence of the EGFR driver mutation was higher in Asian NSCLC; 32% in Asians while 7% in non-Asians ([@bib9]). Currently, the acquired resistance to EGFR-TKIs is an emerging clinical issue. The putative mechanisms of the acquired resistance may include T790M secondary mutations, loss of PTEN and activations of c-Met axis. The c-Met axis activations may include c-Met amplification, c-Met overexpression and hepatocyte growth factor (HGF) upregulation ([@bib20]).

A receptor tyrosine kinase, c-Met, and its ligand, HGF, are overexpressed in many types of cancer, including NSCLC, and may contribute to driving cancer cell proliferation and dissemination, thus leading to disease progression and metastasis ([@bib22]; [@bib24]; [@bib2]; [@bib26]). In addition, the c-Met axis activations have been observed in NSCLC regardless of EGFR mutation status and are correlated with poor prognosis ([@bib1]; [@bib12]; [@bib13]; [@bib21]).

Tivantinib (formerly ARQ 197) is a selective, oral, non-ATP-competitive, small-molecule inhibitor of c-Met ([@bib3]) under extensive clinical evaluation. Clinical studies of tivantinib have been conducted primarily in Western countries so far. A Western phase II study (ARQ 197-209) indicated clinical benefits of tivantinib in combination with an EGFR-TKI, erlotinib, for patients with previously treated non-squamous NSCLC, and those benefits included significantly prolonged progression-free survival ([@bib17]). The dose of tivantinib used in the Western phase II/III studies in NSCLC was 360 mg BID taken at least 1 h before or 2 h after a meal (i.e., between meals), and was not adjusted for polymorphisms of CYP2C19, which is the key enzyme responsible for metabolising tivantinib. Two major CYP2C19 polymorphisms (CYP2C19\*2 and CYP2C19\*3), which lead to a functional deficiency of CYP2C19, are known, and it is well established that the ratio of the CYP2C19 poor metabolisers (PMs), who are defined as the homozygote of either CYP2C19\*2 or CYP2C19\*3 (excluding wild-type CYP2C19\*1), is around 20% in Asian populations, compared with 3% in Caucasians ([@bib7]; [@bib16]; [@bib19]).

To translate the results from Western studies to the Asian population, we have to consider the two major CYP2C19 polymorphisms. The Western population is comprised mainly of CYP2C19 extensive metabolisers (EMs), who are defined as possessing at least one allele of wild-type CYP2C19\*1. As a result of the greater incidence of PMs in Asian populations, a previous Japanese phase I study enrolled both EMs and PMs into separate cohorts based on the pre-treatment test for CYP2C19 polymorphism (ARQ 197-0701; [@bib25]). This study evaluated the safety of tivantinib as a single agent in solid tumours and found haematological toxicities to be the most common adverse events (AEs) related to tivantinib, regardless of CYP2C19 genotype. On the basis of that study, 360 mg BID and 240 mg BID were identified as recommended doses of tivantinib as a single agent for EMs and PMs, respectively, in the Asian population.

Here we report two open-label phase I studies that evaluated the safety and tolerability of tivantinib in combination with erlotinib among Japanese patients with NSCLC, and identified the recommended phase II doses (RP2Ds). Based on the pre-treatment test for CYP2C19 polymorphism, EMs and PMs were enrolled in ARQ 197-003 and ARQ 197-005 studies, respectively. Primary objectives were to evaluate the safety and tolerability of the combination with continuous daily dosing. Secondary objectives were to evaluate the preliminary antitumour activity and pharmacokinetics. PK evaluation of the dietary effects was needed to match the Western phase III protocol (MARQUEE study), and was conducted only in EMs, who are the majority of the Japanese population ([@bib15]). Potential predictive biomarkers were also investigated.

Patients and methods
====================

Study design
------------

ARQ 197-003 (NCT01069757) and ARQ 197-005 (NCT01251796) were multicentre (two and eight institutes, respectively), open-label, dose-escalating Japanese phase I studies. Based on the genetic test of CYP2C19, EMs and PMs were enrolled in ARQ 197-003 and ARQ 197-005, respectively. Patients received a single dose of tivantinib monotherapy for PK analysis, and after 2--6 days off-drug, the patients started consecutive tivantinib in combination with erlotinib (150 mg QD). Tivantinib was supplied by the sponsor as capsules, and was orally administrated twice a day at least 1 h before or 2 h after a meal (i.e., between meals) or just after meals. As shown in [Table 1](#tbl1){ref-type="table"}, the tested doses were escalated from 300 to 360 mg BID of tivantinib in ARQ 197-003 (EM study) and from 120 to 240 mg BID in ARQ 197-005 (PM study). The maximum doses of these studies were decided based on the RP2Ds for tivantinib monotherapy in a previous Japanese phase I study (ARQ 197-0701; [@bib25]). Cohort expansion took place only if dose-limiting toxicity (DLT) was reported in one patient for each cohort during the tolerability evaluation period (defined as the interval from the first dose of tivantinib to day 29 of the combination therapy). Dose escalation stopped if DLTs were observed in two or more patients during one cohort. A DLT was an AE related to either or both of the investigational drugs (i.e., tivantinib and/or erlotinib), and was defined as grade ⩾3 non-haematological toxicity except for controllable nausea, vomiting and diarrhoea, and/or grade ⩾4 haematological toxicity. Toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Patients were allowed to continue tivantinib treatment with erlotinib as long as there was no evidence of progression disease (PD) or safety issues.

These studies were conducted in accordance with institutional guidelines, Good Clinical Practice guidelines and the Declaration of Helsinki. Documented approvals from the Institutional Review Boards were obtained. All patients gave written informed consent.

Eligibility criteria
--------------------

Patients with cytologically or histologically confirmed advanced or recurrent NSCLC were candidates for these studies. The patients also met the inclusion criteria: one or more prior regimens of chemotherapy or EGFR-TKI therapy, ⩾20 years of age, an Eastern Cooperative Oncology Group performance status (ECOG PS; [@bib11]) of ⩽1, a life expectancy of ⩾3 months, adequate organ functions and contraception for a designated period. Patients were excluded if they had prior anticancer therapies within 4 weeks, blood transfusion and/or colony-stimulating factor therapy within 2 weeks, previous tivantinib treatment, family history of QTc-prolongation syndrome, digestive organ dysfunction affecting tivantinib and/or erlotinib absorption, symptomatic CNS metastasis, and an uncontrollable concurrent illness. Pregnant or lactating women were also excluded.

Patient evaluation
------------------

Baseline evaluation included vital signs, blood counts, serum biochemistry and electrocardiograms, as well as genotyping of CYP2C19 and tumour evaluation. Vital signs, blood counts and serum biochemistry were measured every week for the first 4 weeks, and thereafter, every 2 weeks. In addition, electrocardiograms were taken every 2 weeks, and tumour response was evaluated at 4 weeks after the beginning of treatment, and thereafter, every 6 weeks, according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.0. ([@bib23]). Tumour evaluation was conducted based on objective response rate (ORR), which consists of complete response (CR) and partial response (PR), and disease control rate (DCR), which consists of CR, PR and stable disease (SD). Adverse events were assessed continuously throughout the studies.

Pharmacokinetics analysis
-------------------------

PK blood samples were obtained at protocol-defined time points after the first dose of tivantinib (before dosing and 1, 2, 4, 6, 10, 12 and 24 h following tivantinib), and after the first dose of the combination (before dosing and 1, 2, 4, 6, 10 and 12 h following tivantinib on day 1, and before dosing on days 15 and 29). Plasma samples were analysed using liquid chromatography/tandem mass spectrometry. Noncompartmental PK parameters were calculated using Phoenix WinNonlin 6.1 (Pharsight, Mountain View, CA, USA). Dietary effect was also tested in EMs by comparing the PK parameters between cohorts 2 (between meals) and cohort 3 (just after meals), as shown in [Table 1](#tbl1){ref-type="table"}.

Predictive biomarkers
---------------------

Tumour tissue samples were provided as a part of archived tissue or fresh biopsied samples before the first dose of tivantinib, and plasma samples were obtained on the day of the first dose of tivantinib before treatment. Phospho-c-Met (p-c-Met) and c-Met were determined by immunohistochemistry (IHC), by using anti-p-c-Met rabbit monoclonal (clone 130H2, Cell Signaling Technology, Inc., Danvers, MA, USA) and anti-c-Met rabbit polyclonal (Santa Cruz Biotechnology, Inc., Dallas, TX, USA), c-Met amplification by fluorescence *in situ* hybridisation, serum HGF and plasma VEGF by enzyme-linked immunosorbent assay, and EGFR and KRAS mutation status by direct sequencing. Those analyses were conducted in a commercial laboratory (SRL, Inc., Tokyo, Japan) except for EGFR mutation status in some patients, for whom EGFR mutation status had been already diagnosed before their informed consent.

Results
=======

Patient characteristics
-----------------------

A total of 25 patients with advanced or recurrent NSCLC (EMs: *n*=16, PMs: *n*=9) were enrolled into two studies (ARQ 197-003 for EMs and ARQ 197-005 for PMs) from March 2010 to March 2011. The data cutoff date was 28 October 2011 in both studies. Extensive metabolisers and PMs were assigned to each cohort as described in [Table 1](#tbl1){ref-type="table"}. There was no notable difference in patient characteristics between EMs and PMs ([Table 2](#tbl2){ref-type="table"}).

Safety and tolerability
-----------------------

One of 16 patients in ARQ 197-003 was excluded from DLT evaluation because of the study medication compliance of below 75% and no DLT during the tolerability evaluation period. Among the remaining 24 patients in both studies, no DLT was observed during the tolerability evaluation period. Tivantinib in combination with erlotinib was generally well tolerated. Grade 3 nausea and vomiting occurred in one EM patient during the tolerability evaluation period. This patient recovered from these events after antiemetic medications and 1 week of study drug interruption, and then was restarted on study drug at the initial doses with antiemetic prophylaxis.

At the time of the data cutoff, four patients (one in cohort 3 of EMs; one in cohort 1 and two in cohort 2 of PMs) have been ongoing while 21 patients had discontinued the treatment with the investigational drugs. Progression disease is the reason for the discontinuation in 20 of the 21 patients, except one neutropenia related to the investigational drugs, tivantinib and erlotinib. The neutropenia occurred on day 8 of the combination therapy, and the patient was withdrawn from this study according to a discontinuation criterion (i.e., interruption of investigational drugs lasting \>14 days). The median duration from the first dose of tivantinib to the final dosing of tivantinib was 71.5 days (range, 1 to 258+) for EMs and 134.0 days (range, 48 to 303+) for PMs. One EM patient was discontinued because of PD before scheduled day 1 of the combination therapy.

[Table 3](#tbl3){ref-type="table"} shows the common AEs related to the investigational drugs, and the events with a frequency of \>20% throughout the studies, in either or both EMs and PMs. Rash, diarrhoea, dry skin, nausea and stomatitis were commonly observed events in both EMs and PMs and were experienced in \>25% of patients. The grade ⩾3 drug-related AEs that were commonly observed throughout the studies were haematologic toxicities: leukopenia, anaemia and neutropenia. Those grade ⩾3 haematologic toxicities were prone to occur concurrently. A total of six grade ⩾3 haematologic toxicities occurred in three patients; one EM patient developed anaemia, one PM patient developed leukopenia, anaemia and neutropenia, and the remaining PM patient developed leukopenia and neutropenia. Almost all non-haematologic toxicities were grade \<2, except controllable nausea, vomiting and rash. A suspicion of interstitial lung disease was reported in one patient three weeks after the last doses of investigational drugs.

One PM patient developed sepsis, which was recognised as a serious AE (SAE) related to the investigational drugs. The SAE required hospitalisation and treatment interruption of the investigational drugs. The sepsis occurred on day 53 of the combination therapy, with accompanying leukopenia and neutropenia, which had continued since day 30. The patient recovered from the sepsis after 14 days by treatment with granulocyte colony-stimulating factor and antibiotics. However, during the recovering period, the patient developed a PD, which led to the discontinuation from this study.

Pharmacokinetics
----------------

Pharmacokinetic sampling was performed in all 25 patients. [Figure 1](#fig1){ref-type="fig"} shows plasma concentration-time profiles of tivantinib after the first dose of tivantinib and on day 1 of the combination therapy. In EM cohort 3 (360 mg BID, just after meals), the plasma AUC~0-12~ of tivantinib was 18 100±9400 ng h ml^--1^ for tivantinib monotherapy and 18 800±7800 ng h ml^--1^ for the combination. In the PM cohort 2 (240 mg BID, just after meals), the plasma AUC~0-12~ of tivantinib was 27 200±5300 ng h ml^--1^ for tivantinib monotherapy and 27 400±5800 ng h ml^--1^ for the combination. Poor metabolisers treated with 240 mg BID of tivantinib showed moderately higher exposure of tivantinib than EMs treated with 360 mg BID. On the other hand, the AUC~0-12~ was not obviously different in both EMs and PMs when tivantinib was administered alone or in combination with erlotinib. Dietary effects were also tested in EMs by comparing the PK parameters between cohorts 2 and 3, as shown in [Table 1](#tbl1){ref-type="table"}. The AUC~0-12~ for the tivantinib monotherapy was similar between 'between meals\' and 'just after meals,\' that is, 14 800±7700 and 18 100±9400 ng h ml^--1^, respectively. Similarly, the AUC~0-12~ for the combination was similar between cohorts 2 and 3, that is, 20 000±6100 and 18 800±7800 ng h ml^--1^, respectively.

Efficacy and predictive biomarkers
----------------------------------

All 25 patients in these studies were evaluable for tumour response, and the best overall response observed was: 3 PR, 10 SD, 9 PD and 3 non-CR/PD. The ORR was 12.0% and the DCR was 52.0%. Clinically meaningful efficacy was reported in 6 of 25 patients, including 3 PRs and 3 long-term SD of \>24 weeks; 2 of 3 PR patients experienced long-term disease control continuing \>24 weeks on the combination therapy. Molecular properties of these six patients were shown in [Figure 2](#fig2){ref-type="fig"} and those of all patients in Supplement 1. Of the three PR patients, one patient possessed wild-type EGFR with high expression of c-Met (IHC), whereas the other two patients possessed mutated EGFR with various c-Met expressions.

Discussion
==========

The dose-escalating phase I studies herein aimed to assess the safety, tolerability and RP2D of tivantinib in combination with the clinical dose of erlotinib (150 mg QD) in Japanese patients with NSCLC. The patients were separately enrolled in two studies (ARQ 197-003 and ARQ 197-005), which consisted of CYP2C19 EMs and PMs, respectively. The tested dose of tivantinib was up to 360 mg BID for EMs and 240 mg BID for PMs, which were RP2Ds for tivantinib monotherapy determined by a previous Japanese phase I study (ARQ 197-0701).

In the ARQ 197-003 that included only EMs, no DLT was observed in any cohort during the tolerability evaluation period. Throughout this study, anaemia, rash, nausea and vomiting comprised the grade ⩾3 AEs related to the investigational drugs. Each of the AEs occurred once in each of two patients, and resolved by adequate concomitant therapies or the study drug interruption. All these AEs are well known in either tivantinib or erlotinib monotherapies ([@bib8]; [@bib10]; [@bib25]). Taken together, tivantinib treatment at the dose of up to 360 mg BID (with or just after meals) in combination with erlotinib was tolerable and manageable in Japanese EMs with NSCLC. In addition, the AUC (geometric mean) of tivantinib in Japanese NSCLC patients (EM) at 360 mg BID (just after meals) in combination with erlotinib was approximately two-fold higher than that of Caucasians under the same conditions ([@bib5]). Furthermore, the DCR in EMs in this study (50.0%) was not remarkably different from that observed in the phase II Western clinical trial (ARQ 197-209, 64.4% [@bib17]). Therefore, we determined the RP2D in Japanese EMs to be 360 mg BID just after meals, although no DLT was observed in EMs during the tolerability evaluation period in any cohort. This dose and usage are the same as those in phase III studies in Western countries, where EMs comprise the majority of patients.

Similarly, in the ARQ 197-005 trial, which included only PMs, no DLT was observed in any cohort during the tolerability evaluation period. Throughout this study, anaemia, leukopenia, neutropenia and sepsis comprised the grade ⩾3 AEs related to the investigational drugs. These AEs were observed in two of the six patients in cohort 2 (240 mg BID) but were resolved by adequate concomitant therapy and/or drug interruption. All these AEs are well-known for either tivantinib or erlotinib as a single agent ([@bib25]). Hence, tivantinib treatment at a dose of up to 240 mg BID (just after meals) in combination with erlotinib was well tolerated in Japanese PMs with NSCLC. PK analysis in this study demonstrated that plasma exposure of tivantinib in PMs at 240 mg BID (just after meals) was higher than that observed for EMs at 360 mg BID (just after meals). Thus, dose escalation was suspended in PMs at the 240 mg BID dose, although no DLT was observed in PMs during the tolerability evaluation period in any cohort. Regarding efficacy, despite the fact that PMs received smaller doses of tivantinib than EMs, DCR in PMs in this study (55.5%) was not remarkably different from both DCRs in EMs in this study (50.0%) or in comparison with the phase II Western clinical trial (ARQ 197-209, 64.4% [@bib17]). Therefore, the RP2D in Japanese PMs was determined to be 240 mg BID when administered just after meals.

In both the ARQ 197-003 and ARQ 197-005 studies, the common non-haematological toxicities related to the investigational drugs were rash, diarrhoea and dry skin, which were not common for tivantinib monotherapy in the previous study ([@bib25]). It is widely known that rash, diarrhoea and dry skin are among the most common AEs related to erlotinib as a single agent ([@bib8]; [@bib10]). On the other hand, the common haematological toxicities related to the investigational drugs were neutropenia, leukopenia and anaemia. In contrast to non-haematological toxicities, these haematological toxicities have not been frequently observed in erlotinib monotherapy, but were very common in tivantinib monotherapy ([@bib25]). Therefore, tivantinib treatment in combination with erlotinib resulted in only known haematologic or non-haematologic toxicities observed in tivantinib or erlotinib alone. Furthermore, the combination did not increase the incidence of known toxicities in each monotherapy. Thus, tivantinib was compatible with erlotinib when it was administered up to the RP2Ds determined in these studies.

In these studies, the clinically meaningful activities, such as PR, long-term SD or disease control, were seen in six NSCLC patients with various molecular properties (i.e., EGFR mutation, c-Met amplification and c-Met high expression). In two of the six patients in whom the combination treatment of tivantinib and erlotinib resulted in clinically meaningful outcomes, our biomarker study implied c-Met contribution in their disease progression of NSCLC; one patient possessed wild-type EGFR with c-Met high expression, whereas the other patient possessed mutated EGFR with c-Met amplification. Owing to the small sample size of these studies, the specific biomarkers associated with the clinical benefits of combination therapy could not be identified. However, these studies might be encouraging for further trials to evaluate the efficacies of this combination in various molecularly diagnosed NSCLCs. Recently, the Western phase III MARQUEE study enrolled approximately 1000 NSCLC patients irrespective of EGFR mutation and c-Met expression status but was halted early because of futility in a planned interim analysis. Further exploratory analyses were performed, and the MET high tivantinib group showed a substantial improvement in OS relative to control ([@bib14]).

In conclusion, tivantinib, when combined with erlotinib, was well tolerated up to 360 mg BID for EMs and 240 mg BID for PMs, and therefore these doses were determined as RP2Ds. These results warrant further investigation of this combination in phase II NSCLC studies conducted in the Japanese/Asian population.
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Click here for additional data file.

![**Pharmacokinetics profiles of tivantinib.** Plasma concentration-time profiles of tivantinib after tivantinib monotherapy and the first dose of tivantinib in combination with erlotinib on day 1 are shown. Each point represents the mean±s.d. for EMs (left panel) and PMs (right panel), respectively.](bjc2013588f1){#fig1}

![**Spider plot and molecular properties of the six patients with a clinically meaningful efficacy.** Changes of tumour sizes are shown for patients who had measurable lesions (22 of 25 patients). Sums of the diameters of the target lesions are demonstrated as changes from baseline. The red and blue lines indicate individual EM and PM, respectively. Molecular properties of tumours are shown for particular individual patients. Among the molecular properties, positive c-Met amplification was defined as ⩾4 copy numbers of c-Met gene (fluorescence *in situ* hybridisation). High c-Met IHC was defined as a higher IHC score than the median; all others were considered low ([Supplement 1](#sup1){ref-type="supplementary-material"}).](bjc2013588f2){#fig2}

###### Patient enrolment

  **ARQ 197-003 (EM patients)**                                                                                
  ------------------------------- ----------------------------- ------------------------- -------------------- ------------------------------
  1                               300 mg BID between meals      150 mg QD between meals         3+3 Rule        4[a](#t1-fn2){ref-type="fn"}
  2                               360 mg BID between meals      150 mg QD between meals            6                         6
  3                               360 mg BID just after meals   150 mg QD between meals            6                         6
                                                                                                                              
  **ARQ 197-005 (PM patients)**                                                                                
  **Cohort**                      **Tivantinib**                **Erlotinib**              **Planned number**        **Actual number**
  1                               120 mg BID just after meals   150 mg QD between meals         3+3 Rule                     3
  2                               240 mg BID just after meals   150 mg QD between meals            6                         6

Abbreviations: EM=extensive metaboliser; PM=poor metaboliser.

One patient was replaced because of tivantinib-unrelated adverse event that led to an insufficient compliance to evaluate the safety of the dose level.

###### Patient characteristics

                                              **EM**   **PM**   **Overall**
  ------------------------------------------ -------- -------- -------------
  Patient number                                16       9          25
  **Age (years)**                                              
  Median                                       61.5     61.0        ---
  **Gender**                                                   
  Male                                          6        6          12
  Female                                        10       3          13
  **Diagnosis[a](#t2-fn2){ref-type="fn"}**                     
  Advanced                                      15       7          22
  Recurrent                                     1        2           3
  **Number of prior chemotherapy**                             
  1                                             4        1           5
  2                                             4        2           6
  ⩾3                                            8        6          14
  **Prior EGFR-targeted treatment**                            
  Yes                                           4        5           9
  No                                            12       4          16
  **EGFR status**                                              
  Mutation                                      8        5          13
  Wild-type                                     5        3           8
  Unknown                                       3        1           4
  **ECOG PS**                                                  
  0                                             6        2           8
  1                                             10       7          17

Abbreviations: ECOG PS=Eastern Cooperative Oncology Group performance status; EGFR=epidermal growth factor receptor; EM=extensive metaboliser; PM=poor metaboliser.

Advanced: metastatic at first diagnosis. Recurrent: recurrent following surgery and/or radiation therapy.

###### Drug-related adverse events occurring \>20% of either or both of EMs and PMs, throughout the studies

                           **EM (*****n*****=16)**   **PM (*****n*****=9)**   **Overall (*****n*****=25)**                      
  ------------------------ ------------------------- ------------------------ ------------------------------ -------- --------- -------
  **Haematological**                                                                                                            
   Leukopenia              3 (19)                    0 (0)                    3 (33)                         2 (22)   6 (24)    2 (8)
   Anaemia                 4 (25)                    1 (6)                    1 (11)                         1 (11)   5 (20)    2 (8)
   Neutropenia             1 (6)                     0 (0)                    2 (22)                         2 (22)   3 (12)    2 (8)
   Lymphopenia             1 (6)                     0 (0)                    2 (22)                         0 (0)    3 (12)    0 (0)
  **Non-haematological**                                                                                                        
   Rash                    13 (81)                   1 (6)                    9 (100)                        0 (0)    22 (88)   1 (4)
   Diarrhoea               9 (56)                    0 (0)                    2 (22)                         0 (0)    11 (44)   0 (0)
   Dry skin                8 (50)                    0 (0)                    3 (33)                         0 (0)    11 (44)   0 (0)
   Nausea                  5 (31)                    1 (6)                    2 (22)                         0 (0)    7 (28)    1 (4)
   Stomatitis              5 (31)                    0 (0)                    2 (22)                         0 (0)    7 (28)    0 (0)
   Dysgeusia               5 (31)                    0 (0)                    1 (11)                         0 (0)    6 (24)    0 (0)
   Anorexia                4 (25)                    0 (0)                    2 (22)                         0 (0)    6 (24)    0 (0)
   Other skin disorder     4 (25)                    0 (0)                    2 (22)                         0 (0)    6 (24)    0 (0)
   Fatigue                 3 (19)                    0 (0)                    3 (33)                         0 (0)    6 (24)    0 (0)
   Nail disorder           3 (19)                    0 (0)                    2 (22)                         0 (0)    5 (20)    0 (0)
   Vomiting                4 (25)                    1 (6)                    0 (0)                          0 (0)    4 (16)    1 (4)
   Sinus bradycardia       0 (0)                     0 (0)                    2 (22)                         0 (0)    2 (8)     0 (0)

Abbreviations: EM=extensive metaboliser; PM=poor metaboliser.
